New Release: ProFine®

ProFine® is now available at our online store as well as at www.Amazon.com.

ProFine® Description:

• A unique combination of three naturally-occurring bioflavonoids 
• Improves prostate, cardiovascular and overall health
• Pure flavonoids; gluten, wheat and dairy free
• Registered trademark SN 86-915,479
• Patent pending (US 2017/0087125 A1)
• Reference: A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. Neoplasia. 2018 Aug;20(8):789-799. doi: 10.1016/j.neo.2018.06.003.

The Journey Begins

Thanks for joining me!

Good company in a journey makes the way seem shorter. — Izaak Walton

New STTR grant

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound and its use in treating bone metastatic castration-resistant prostate cancer.

New STTR grant supporting GH501 study

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This grant is to support the research on a potent small-molecule compound GH501 and its use in treating bone metastatic castration-resistant prostate cancer.

New STTR grant

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound in treating prostate cancer.

New STTR grant supporting BKM1644 study

MetCure received a $224,999 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the mechanism of action and in vivo efficacy of a novel small-molecule compound (BKM1644) in treating prostate cancer.

Project Details:

Enzalutamide resistance is a major obstacle in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). Recently we developed a small-molecule lead compound BKM1644 and demonstrated its potent activity against bone metastatic prostate cancer cells. In this Phase I STTR application, we hypothesize that BKM1644 is a novel targeted therapy to overcome enzalutamide resistance and effectively target bone metastasis. Two Aims are proposed: Aim 1 will evaluate the in vivo pharmacokinetics, distribution and efficacy of BKM1644 in targeting enzalutamide-resistant, bone metastatic prostate cancer in animal models. Aim 2 will determine the mechanism of action of BKM1644 in mCRPC cells. The project has immediate therapeutic potential in treating a lethal disease.

Phase I STTR grant supporting ProFine® study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine® in enhancing standard prostate cancer therapy.

Phase I STTR grant supporting ProFine(R) study

MetCure received a $160,996 Phase I Small Business Technology Transfer (STTR) grant from the National Cancer Institute. This project is to investigate the efficacy of a novel nutraceutical agent ProFine in enhancing standard prostate cancer therapy.